Ancobon Side Effects
Generic name: flucytosine
Note: This document contains side effect information about flucytosine. Some of the dosage forms listed on this page may not apply to the brand name Ancobon.
Some side effects of Ancobon may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
For the Consumer
Applies to flucytosine: oral capsule, oral tablet
Along with its needed effects, flucytosine (the active ingredient contained in Ancobon) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking flucytosine:More common
- Skin rash, redness, or itching
- sore throat and fever
- unusual bleeding or bruising
- unusual tiredness or weakness
- yellow eyes or skin
- hallucinations (seeing, hearing, or feeling things that are not there)
- increased sensitivity of skin to sunlight
Some side effects of flucytosine may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:More common
- Abdominal pain
- loss of appetite
- nausea or vomiting
- Dizziness or lightheadedness
For Healthcare Professionals
Applies to flucytosine: oral capsule
Gastrointestinal side effects have included nausea, emesis, abdominal pain, diarrhea, anorexia, dry mouth, duodenal ulcer, gastrointestinal hemorrhage, enterocolitis, and ulcerative colitis.
Nausea is common at high doses, generally occurs in the first two weeks of therapy, and often resolves with time or temporary dose reduction. Diarrhea is often associated with cramps, occurs most frequently in the first two weeks of therapy, and frequently resolves with time or temporary dose reduction. One case has been reported of a patient on long-term therapy who developed diarrhea which did not resolve spontaneously. X-ray of the small bowel revealed ulceration and the ileocecal valve and distal ileum appeared edematous. Flucytosine was discontinued and the patient improved over the next two weeks.
Some patients experience significant increases in liver function tests and may develop signs and symptoms of hepatitis. Liver function test abnormalities generally resolve after discontinuation of flucytosine (the active ingredient contained in Ancobon)
Hepatic side effects have included jaundice, hepatic dysfunction, bilirubin elevation, increased hepatic enzymes, and acute hepatic injury including hepatic necrosis with possible fatal outcome in debilitated patients.
Hematologic side effects have included anemia, agranulocytosis, aplastic anemia, eosinophilia, leukopenia, pancytopenia, thrombocytopenia, and fatal cases of bone marrow suppression.
Bone marrow suppression may range from isolated leukopenia or thrombocytopenia to pancytopenia. Often there is just mild leukopenia or thrombocytopenia which does not require discontinuation of the drug. In most cases the suppression is reversible following discontinuation of flucytosine therapy, but at least one case of fatal, irreversible marrow failure has occurred.
Photosensitivity has been reported in one case of a patient receiving long-term flucytosine (the active ingredient contained in Ancobon) The photosensitivity persisted for one year after completion of therapy.
A case of anaphylaxis has been reported. In that case, a patient who had hemophilia and AIDS was receiving flucytosine for oral candidiasis. Flucytosine therapy was started following 10 days of miconazole and the patient developed a fever, erythema, pruritus, tachycardia and hypotension requiring volume support. Rechallenge was attempted one week later with one tablet. The rechallenge resulted in the same signs and symptoms and ran a similar course.
Hypersensitivity side effects have included allergic reactions. Rashes have been reported rarely. At least one case of photosensitivity has been reported, in addition to a case of anaphylaxis.
A 34-year-old woman reported severe chest pain the day after completing a 2-day flucytosine (the active ingredient contained in Ancobon) therapy. Cardiac echography indicated septo-apico-lateral severe hypokinesia, with left ventricular ejection fraction less than 15%. Aggressive cardiac intensive care with positive inotropic agents, placement of an intra-aortic balloon pump counterpulsation, and milrinone along with continuous veno-venous hemodiafiltration were needed over the 2 weeks of hospitalization before restoration of her cardiovascular status. Patient has not shown further signs of heart problems during the 2 years since this event.
Cardiovascular side effects have included cardiac arrest, myocardial toxicity, and ventricular dysfunction. Cardiac toxicity with ST elevation has been reported in a 34-year-old woman, with no previous history of heart disease, the day after completing a 2-day flucytosine therapy.
Respiratory side effects have included dyspnea, chest pain, and respiratory arrest.
Dermatologic side effects have included rash, pruritus, urticaria, photosensitivity, and Lyell's syndrome.
Genitourinary side effects have included crystalluria.
Renal side effects have included azotemia, creatinine and BUN elevation, and renal failure.
Nervous system side effects have included ataxia, hearing loss, headache, paresthesia, parkinsonism, peripheral neuropathy, pyrexia, vertigo, sedation, and convulsions.
Psychiatric side effects have included confusion, hallucinations, and psychosis.
Metabolic side effects have included hypoglycemia.
Other side effects have included fatigue and weakness.
More Ancobon resources
- Ancobon Prescribing Information (FDA)
- Ancobon MedFacts Consumer Leaflet (Wolters Kluwer)
- Ancobon Concise Consumer Information (Cerner Multum)
- Ancobon Advanced Consumer (Micromedex) - Includes Dosage Information
- Ancobon Monograph (AHFS DI)
- Flucytosine Prescribing Information (FDA)
- Flucytosine Professional Patient Advice (Wolters Kluwer)
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.